Composition for preventing or treating sleep disorders comprising above-ground parts of sedum kamtschaticum

The *Girinchō* extract addresses the limitations of conventional sedatives by enhancing sleep induction through A2A receptors and GABA release, effectively reducing sleep latency and increasing total sleep time in both pharmaceutical and food compositions.

WO2026240293A1PCT designated stage Publication Date: 2026-11-19KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2025/021673
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-14
Filing Date
2025-12-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Conventional sedatives for treating sleep disorders have safety issues and can lead to dependence, while natural alternatives are lacking in efficacy and specificity for sleep induction.

Method used

A pharmaceutical and food composition using a *Girinchō* extract as an active ingredient, which includes compounds that enhance sleep induction through A2A receptors and GABA release, formulated into various dosage forms for oral and parenteral administration.

Benefits of technology

The *Girinchō* extract effectively reduces sleep latency and increases total sleep time, addressing sleep disorders by promoting sleep through A2A receptor activation and GABA release, with identified compounds showing significant sleep-inducing effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2025021673_19112026_PF_FP_ABST
    Figure KR2025021673_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition for preventing or treating sleep disorders, the composition comprising a Sedum Kamtschaticum extract as an active ingredient. The present invention is based on the finding that an ethanol extract of Sedum kamtschaticum has the sleep disorder-alleviating effect of increasing sleep time and induces sleep using an A2A receptor. In addition, compounds in the ethanol extract of Sedum kamtschaticum were identified, and a compound having excellent GABA-releasing capacity as a sleep-inducing effect was selected from among compounds derived from the ethanol extract of Sedum kamtschaticum.
Need to check novelty before this filing date? Find Prior Art

Description

A composition for the prevention or treatment of sleep disorders containing a substance derived from the above-ground parts of *Girinchō*.

[0001] The present invention relates to a composition for the prevention or treatment of sleep disorders comprising a *Girinchō* extract as an active ingredient.

[0002] Sleep can be defined from various perspectives, but it is primarily defined as an immobile state in which the ability to perceive and respond to the external environment is reversibly, repeatedly, and normally suspended. While this sleep is driven by brain activity, it is also deeply linked to physiological changes in other parts of the body.

[0003] Sleep disorders are one of the common problems faced by modern people, and are a very common condition in which more than 20% of the population has either experienced or suffers from it. These sleep disorders refer to a state in which one is unable to get healthy sleep, fails to maintain wakefulness during the day despite getting sufficient sleep, or experiences difficulty sleeping or staying awake due to a disrupted sleep rhythm. Mental health issues can also be a major cause, stemming from excessive stress, anxiety, tension, and fear.

[0004] Sleep disorders can lead to various personal and social problems and are the cause of learning disabilities, reduced efficiency, traffic accidents, safety accidents, emotional disorders, social maladjustment, marital dissatisfaction, and industrial accidents. Furthermore, if sleep disorders are not treated properly, pre-existing medical, neurological, and psychiatric conditions may worsen or recovery may be delayed, potentially leading to serious illnesses such as myocardial infarction and stroke.

[0005] To treat these sleep disorders, chemical sedatives are used to induce and maintain sleep by reversibly suppressing the central nervous system. Conventional sedatives have a central depressant effect similar to anesthetics; while they cause sedation at low doses and sleep at medium doses, high doses lead to coma, paralysis, and respiratory depression. Barbiturates have low safety profiles, leading to tolerance and dependence; furthermore, discontinuing them after prolonged use can cause sleep disorders such as nightmares.

[0006] Accordingly, the inventors confirmed that the extract of *Girinchō* has a sleep-inducing effect and completed the present invention.

[0007] The object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of sleep disorders comprising a *Girinchō* extract as an active ingredient.

[0008] Another objective of the present invention is to provide a food composition for the prevention or improvement of sleep disorders comprising a *Girinchō* extract as an active ingredient.

[0009] Another objective of the present invention is to provide a pharmaceutical composition for the prevention or treatment of sleep disorders comprising a compound derived from *Girinchō* as an active ingredient.

[0010] Another objective of the present invention is to provide a food composition for the prevention or improvement of sleep disorders comprising a compound derived from *Girinchō* as an active ingredient.

[0011] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of sleep disorders comprising a *Girinchō* extract as an active ingredient.

[0012] In addition, the present invention provides a food composition for the prevention or improvement of sleep disorders comprising a succulent plant extract as an active ingredient.

[0013] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of sleep disorders comprising a compound derived from *Girinchō* as an active ingredient.

[0014] In addition, the present invention provides a food composition for the prevention or improvement of sleep disorders comprising a compound derived from *Girinchō* as an active ingredient.

[0015] The present invention confirmed that the ethanol extract of *Scutellaria baicalensis* has an effect of improving sleep disorders by increasing sleep time and inducing sleep using A2A receptors. In addition, compounds within the ethanol extract of *Scutellaria baicalensis* were identified, and among the compounds derived from the ethanol extract of *Scutellaria baicalensis*, compounds with excellent GABA release ability for sleep induction effects were selected, which can be usefully utilized in related industries.

[0016] Figure 1 is a figure quantifying the sleep-inducing effect according to treatment with the Girincho extract of the present invention (A: quantification of sleep latency, B: quantification of total sleep time).

[0017] Figure 2 is a figure confirming the A2A receptor association of the *Girinchō* extract of the present invention (A: quantification of sleep latency, B: quantification of total sleep time).

[0018] Figure 3 is a figure confirming the brain sleep-wake regulating effect of the Girincho extract of the present invention by immunohistochemical staining.

[0019] Figure 4 is a figure confirming the A2A receptor binding affinity of the *Girinchō* extract of the present invention.

[0020] Figure 5 is a figure showing the metabolite profiling results included in the Girincho extract of the present invention.

[0021] Figure 6 is a figure showing the compound content of the Girincho extract of the present invention according to the solvent, confirmed by HPLC.

[0022] Figure 7 is a figure showing the QTOF / MS results of compounds included in the Girincho extract of the present invention (A: Compound 1, B: Compound 2, C: Compound 3).

[0023] Figure 8 shows the QTOF / MS results of compounds included in the Girincho extract of the present invention (A: Compound 4, B: Compound 5, C: Compound 6).

[0024] Figure 9 shows the QTOF / MS results of compounds included in the Girincho extract of the present invention (A: Compound 7, B: Compound 8).

[0025] Figure 10 is a figure showing the QTOF / MS results of compounds included in the Girincho extract of the present invention (A: Compound 9, B: Compound 10).

[0026] Figure 11 is a figure quantifying the compounds and compound content according to the solvent of the Girincho extract of the present invention.

[0027] Figure 12 is a figure showing the GABA release ability confirmed to verify the sleep improvement effect of the compound derived from the Girincho extract of the present invention.

[0028] Embodiments of the present invention will be described in detail below with reference to the attached drawings. In the following description, detailed descriptions of technologies well known to those skilled in the art may be omitted. Furthermore, in describing the present invention, detailed descriptions of related known functions or configurations may be omitted if it is determined that such descriptions would unnecessarily obscure the essence of the present invention. Additionally, the terminology used in this specification is used to appropriately express preferred embodiments of the present invention, and may vary depending on the intent of the user or operator, or the conventions of the field to which the present invention belongs.

[0029] Therefore, the definitions of these terms should be based on the content throughout this specification. Throughout the specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0030] The present invention provides a pharmaceutical composition for the prevention or treatment of sleep disorders comprising a succulent plant extract as an active ingredient.

[0031] The term “prevention” as used in this invention refers to any act of suppressing the symptoms of a specific disease or delaying its progression through the administration of the composition of this invention.

[0032] The term “treatment” as used in this invention refers to any act of improving or beneficially altering the symptoms of a specific disease through the administration of the composition of this invention.

[0033] The pharmaceutical composition of the present invention may additionally include an adjuvant in addition to the active ingredient. Any adjuvant known in the art may be used without limitation, but, for example, Freund's complete or incomplete adjuvant may be further included to increase the effect.

[0034] The pharmaceutical composition according to the present invention may be prepared in a form in which an active ingredient is incorporated into a pharmaceutically acceptable carrier. Here, the pharmaceutically acceptable carrier includes carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention are not limited to these, but may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0035] The pharmaceutical composition of the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external formulations, suppositories, or sterile injectable solutions, each according to conventional methods.

[0036] When formulating, the product may be prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and such solid dosage forms may be prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., with the active ingredient. In addition, lubricants such as magnesium stearate and talc may also be used in addition to simple excipients. Liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, and syrups, and may contain various excipients, such as wetting agents, sweeteners, flavoring agents, and preservatives, in addition to commonly used diluents such as water and liquid paraffin. Preparations for parenteral administration include sterile aqueous solutions, water-insoluble solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Water-insoluble solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Bases for suppositories may include Witepsol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc.

[0037] The pharmaceutical composition according to the present invention may be administered to an individual by various routes. Any mode of administration may be anticipated, for example, by oral, intravenous, intramuscular, subcutaneous, or intraperitoneal injection.

[0038] The dosage of the pharmaceutical composition according to the present invention is selected by taking into consideration the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of the active ingredient included in the pharmaceutical composition can be selected in various ways depending on the subject, and preferably, it is included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg / ml. If the concentration is less than 0.01 μg / ml, pharmaceutical activity may not appear, and if it exceeds 5,000 μg / ml, it may exhibit toxicity to the human body.

[0039] According to one embodiment of the present invention, the extract may be extracted with a solvent selected from the group consisting of water, C1 to C4 lower alcohols, aqueous solutions of lower alcohols, hexane, acetone, ethyl acetate, and chloroform.

[0040] According to one embodiment of the present invention, the Girincho extract may induce sleep, and the sleep induction may involve reducing the sleep latency or increasing the total sleep time.

[0041] According to one embodiment of the present invention, the induction of sleep may be A2A receptor-dependent.

[0042] According to one embodiment of the present invention, the *Girinchō* extract may comprise a compound selected from the group consisting of a compound with a mass value of 459.09098 [M+H]+, a compound with a mass value of 633.11094 [M+H]+, ethyl gallate, a compound with a mass value of 639.15515 [M+H]+, pulsatillanin A, quercitrin, 2"-O-galloylmyricitrin, 3"-O-galloylmyricitrin, 2"-O-galloylquercitrin, and 3"-O-galloylquercitrin, and said compound has GABA-free ability It could be something that has.

[0043] According to one embodiment of the present invention, the GABA-releasing ability may induce sleep.

[0044] According to one embodiment of the present invention, the sleep disorder may be a disease selected from the group consisting of insomnia, sleep onset disorder, sleep maintenance disorder, early awakening disorder, deep sleep disorder, circadian rhythm sleep disorder, and sleep apnea, preferably insomnia but not limited thereto.

[0045]

[0046] In addition, the present invention provides a food composition for the prevention or improvement of sleep disorders comprising a succulent plant extract as an active ingredient.

[0047] As used in the present invention, the term “improvement” refers to any action that at least reduces parameters related to the condition being treated, such as the degree of symptoms.

[0048] In addition to containing the active ingredient of the present invention, the food composition of the present invention may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, as in conventional food compositions.

[0049] Examples of the natural carbohydrates described above include monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The flavoring agents described above may advantageously use natural flavoring agents (taumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention may be formulated in the same manner as the pharmaceutical composition described above and used as a functional food or added to various foods. Foods to which the composition of the present invention may be added include, for example, beverages, meat, chocolate, food products, confectionery, pizza, ramen, other noodles, chewing gum, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements.

[0050] In addition, the above food composition may contain, in addition to the extract which is an active ingredient, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, the food composition of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages.

[0051] The functional food composition of the present invention may be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., for the purpose of preventing or treating sleep disorders. In the present invention, the term "health functional food composition" refers to a food manufactured and processed using raw materials or ingredients having functional properties useful to the human body pursuant to Article 6727 of the Act on Health Functional Foods, and means consuming it for the purpose of obtaining effects useful for health uses, such as regulating nutrients or physiological actions regarding the structure and function of the human body. The health functional food of the present invention may include conventional food additives, and unless otherwise stipulated, suitability as a food additive is determined according to the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the Food Additives Codex approved by the Ministry of Food and Drug Safety. Items listed in the aforementioned "Food Additives Codex" include, for example, chemical synthetic compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Examples include natural additives such as persimmon pigment, licorice extract, crystalline cellulose, sorghum pigment, and guar gum; and mixed preparations such as L-sodium glutamate preparations, alkaline additives for noodles, preservative preparations, and tar dye preparations. For example, a health functional food in tablet form may be produced by granulating a mixture of the active ingredient of the present invention with an excipient, a binder, a disintegrant, and other additives using a conventional method, and then adding a lubricant or the like and compression molding, or by directly compression molding the said mixture. In addition, the health functional food in tablet form may contain a binder or the like as needed. Among health functional foods in capsule form, hard capsules may be manufactured by filling a conventional hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules may be manufactured by filling a capsule base such as gelatin with a mixture of the active ingredient of the present invention mixed with additives such as excipients. The above soft capsule may contain plasticizers such as glycerin or sorbitol, coloring agents, preservatives, etc., as needed.A health functional food in the form of a pill can be prepared by molding a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., using a previously known method, and if necessary, it can be coated with sucrose or other coating agents, or the surface can be coated with a substance such as starch or talc. A health functional food in the form of a granule can be prepared by making a mixture of the active ingredient of the present invention, excipients, binders, disintegrants, etc., into a granular form using a previously known method, and may contain flavoring agents, stimulating agents, etc., if necessary.

[0052]

[0053] In addition, the present invention provides a pharmaceutical composition for the prevention or treatment of sleep disorders comprising a compound derived from *Girinchō* as an active ingredient.

[0054] According to one embodiment of the present invention, the compound may be a compound selected from the group consisting of a compound with a mass value of 459.09098 [M+H]+, a compound with a mass value of 633.11094 [M+H]+, ethyl gallate, a compound with a mass value of 639.15515 [M+H]+, pulsatillanin A, quercitrin, 2"-O-galloylmyricitrin, 3"-O-galloylmyricitrin, 2"-O-galloylquercitrin, and 3"-O-galloylquercitrin.

[0055]

[0056] In addition, the present invention provides a food composition for the prevention or improvement of sleep disorders comprising a compound derived from *Girinchō* as an active ingredient.

[0057] The present invention will be explained in more detail below through examples. These examples are merely for the purpose of explaining the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited to these examples.

[0058]

[0059] <Example 1> Preparation for confirming the effect of *Girinchō* extract on improving sleep disorders

[0060] <1-1> Materials and Reagents

[0061] Diazepam, the positive control used in this invention, was purchased from Hanlim Pharmaceutical (Seoul, South Korea). Pentobarbital was purchased from Myungjin Pharmaceutical (Seoul, South Korea), and Luzindole was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), flumazenil (FLU), 2-pyridineethanamine dihydrochloride (PEA), TCB-2, 2-(furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine (SCH58261 or SCH) is Tocris It was purchased from Biosciences (Avonmouth, UK). The rabbit anti-c-Fos antibody was purchased from Cell Signaling Technology (Danvers, MA, USA).

[0062]

[0063] <1-2> Preparation of Girincho Extract

[0064] Ethanol extracts of Phedimus aizoon (ESK) of the present invention were prepared. Specifically, Phedimus aizoon (L.) 't Hart var. floribundus (Nakai) H. Ohba was harvested in Eumseong, Chungbuk, South Korea, and a certified specimen (certification number MPS002559) was stored in the herbarium of the National Institute of Horticultural and Special Crops Science, Rural Development Administration, Eumseong, South Korea. The dried above-ground parts of Phedimus aizoon were mixed with 30% ethanol in a weight ratio of 1:10 and extracted by reflux at 70°C for 5 hours, followed by reduced concentration. Subsequently, the concentrate was dried using a spray dryer to produce ESK.

[0065] In addition, a hot water extract of *Girinchō* was prepared by changing the solvent to water and reflux extraction using the same method as above.

[0066]

[0067] <1-3> Preparing Animal Models

[0068] All animal experiments were conducted in accordance with the guidelines of the Ajou University Animal Ethics Committee (Approval No. 2023-0006), and all animal handling and management procedures were carried out in compliance with the animal care and management guidelines published by Ajou University. Mice were purchased from Orient Bio, Inc. (Seongnam, South Korea), and 8-week-old male ICR mice were used for pentobarbital-induced sleep experiments. 8-week-old male C57BL / 6 mice were used for immunohistochemistry and ELISA experiments. Experimental animals were acclimated by having free access to water and feed in cages with 5 animals per cage, maintaining a temperature of 23±1℃ and a relative humidity of 60±10% under a 12-hour light cycle (8:00-20:00).

[0069]

[0070] <1-4> Pentobarbital-Induced Sleep Experiment

[0071] To confirm the effect of the *Girinchō* extract of the present invention on improving sleep disorders, a pentobarbital-induced sleep experiment was performed. Specifically, pentobarbital and ESK were dissolved in saline solution, and agonists, various receptor antagonists, and desmantine were dissolved in 1% DMSO. Saline solution or 1% DMSO was administered to the control group and the vehicle group, respectively. The control group, vehicle group, diazepam group, and ESK group were orally administered 30 minutes prior to pentobarbital administration, while the agonists and antagonists of various receptors were orally or intraperitoneally administered 45 minutes prior to pentobarbital administration. Afterward, mice were placed in individual cages, and sleep latency was measured as the time until the orientation reflex disappeared, while total sleep time was defined as the time until the orientation reflex recovered.

[0072]

[0073] <1-5> Immunohistochemical staining

[0074] Immunohistochemical staining was performed to confirm the effect of the *Girinchō* extract of the present invention on improving sleep disorders. Specifically, *Girinchō* extract and control samples were administered to mice of each group at 15-minute intervals. After 1 hour, the mice were anesthetized by administering pentobarbital at a concentration of 50 mg / kg. Subsequently, the diaphragm was incised, saline was perfused through the heart, brain tissue was excised, and fixed in 4% paraformaldehyde at 4°C for 24 hours. Afterward, the brain tissue was immersed in a 30% sucrose solution for 48 hours, embedded in an optimal cutting temperature compound, and stored at -80°C for 24 hours. The tubular sections of the excised brain were sectioned to a thickness of 20 μm using a Leica SM2400 microtome (Leica Microsystem Inc., Durham, IL, USA) and stored at -20°C. Subsequently, for antigen recovery, brain tissue sections were incubated at 25°C for 30 minutes and then immersed in 10 mM sodium citrate buffer. The sections were then washed with PBS and treated with 3% H2O2 for 5 minutes to inhibit endogenous activity. Afterward, the sections were blocked at 25°C for 1 hour with PBS containing 0.1% Triton X-100 and 5% BSA added; then, anti-c-Fos primary antibody (1:500) (Cell Signaling Technology, #2250, Danvers, MA, USA) was added to the blocking solution and blocked for 48 hours. Afterward, the sections were washed with PBS, and biotinylated anti-rabbit secondary antibody (1:500) (Vector Laboratories Inc., BA-1000, Newark, CA, USA) was added and incubated for 1 hour.After the reaction was finished, the sections were washed with PBS, stained for 30 minutes using the VECTASTAIN® avidin-biotin complex (ABC) kit (Vector Laboratories, Burlingame, CA, USA), washed, visualized for 5 minutes using the Dako Liquid 3,3'-diaminobenzidine (DAB) + Substrate Chromogen System kit (Agilent, Carpinteria, CA, USA), and brown c-Fos-positive neurons were identified under a light microscope.

[0075]

[0076] In addition, after antigen recovery, brain sections were blocked at 25°C with 5% BSA added to PBS containing 0.1% Triton X-100, and then the sections were treated with anti-c-Fos rabbit antibody (1:400) (Cell Signaling Technology, #2250, Danvers, MA, USA) and anti-GAD67 mouse antibody (1:500) (Millipore, MAB5406, Burlington, MA, USA), incubated at 4°C for 48 hours, and then washed with PBS. Subsequently, goat anti-rabbit Alexa Fluor 568 (1:500) (Invitrogen Corporation, A11011, Carlsbad, CA, USA) and goat anti-mouse Alexa Fluor 488 (1:500) (Invitrogen Corporation, A11029, Carlsbad, CA, USA) were treated and incubated at 25°C for 1 hour. Afterward, the sections were stained with 4′,6-diamidino-2-phenylindole (DAPI; Molecular Probes, Eugene, OR, USA), washed with PBS, and examined under a confocal microscope.

[0077]

[0078] <1-6> Radioligand Receptor Binding Test

[0079] The binding of the *Girinchō* extract of the present invention to the radioligand receptor of A2AR was confirmed. Specifically, the test was performed using HEK-293 cells overexpressing A2AR at Eurofins Pharmacology Services (St. Charles, MO, USA) and tested at ESK concentrations of 0.1, 0.3, and 0.9 mg / ml. Inhibition or stimulation of 50% or more was considered to indicate a significant effect, inhibition or stimulation between 25% and 50% was considered to indicate a mild to moderate effect, and inhibition or stimulation of less than 25% was considered insignificant.

[0080]

[0081] <1-7> ELISA Analysis

[0082] SCH 58261 of the present invention was administered 15 minutes prior to ESK administration. One hour later, mice were anesthetized with pentobarbital sodium, and after perfusing the heart, brain tissue was excised. Subsequently, the hypothalamus was isolated from the brain tissue and homogenized with PBS. The supernatant was then obtained, and GABA levels were analyzed using an ELISA kit.

[0083]

[0084] <1-8> Statistical Analysis

[0085] Experimental data were expressed as mean ± SEM, and statistical analysis was performed using GraphPad Prism 8.0.2 software. Shapiro-Wilk and Kolmogorov-Smirnov tests were used to verify whether the data satisfied the normality assumption; for data that did not satisfy the normality assumption, a nonparametric Kruskal-Wallis test was performed, followed by a one-way analysis of variance (ANOVA) using Tukey's post-hoc test. A p-value less than 0.05 was considered to indicate statistical significance.

[0086]

[0087] <Example 2> Confirmation of the sleep-inducing effect of *Girinchō* extract

[0088] <2-1> Confirmation of the sleep-inducing effect of *Girinchō* extract

[0089] Pentobarbital-induced sleep behavior experiments were conducted to investigate the sleep-improving effects of the *Girinchō* extract. As a result, as shown in Figure 1, it was confirmed that ESK reduced sleep onset latency in a concentration-dependent manner; specifically, at concentrations of 3, 10, and 30 mg / kg, it reduced sleep onset latency to 178.6±3.4, 166.2±3.2, and 159.2±6.0 seconds, respectively. DZP (1 mg / kg), used as a positive control, significantly reduced sleep onset latency and increased total sleep time. Since ESK at a concentration of 30 mg / kg was found to have a sleep-inducing effect similar to that of DZP, subsequent experiments were conducted at a concentration of 30 mg / kg.

[0090]

[0091] <2-2> Confirmation of A2A Receptor Association of *Girinchō* Extract

[0092] As for the sleep-improving effects of the *Girinchō* extract, the sleep onset time and total sleep time were determined using flumazenil, a pentobarbital-induced sleep GABAA receptor antagonist; DPCPX, an adenosine A1 receptor antagonist; SCH, an adenosine A2A receptor antagonist; Luzindol, a melatonin receptor 1 antagonist; PEA, a histamine H1 agonist; TCB-2, a 5-HT2A receptor agonist; and YNT-185, an oryxin 2 receptor agonist. As a result, as shown in Figure 2, it was confirmed that only SCH and ESK decreased the sleep onset time and increased the total sleep time, confirming that ESK is related to the A2A receptor (A2AR).

[0093]

[0094] <2-3> Confirmation of Brain Sleep-Wake Regulation by Girincho Extract

[0095] Immunohistochemical staining was performed to confirm the sleep-wake regulating effect of the *Girinchō* extract. As a result, as shown in Figure 3, the number of c-Fos neurons, which are indicators of neural activity in the ventrolateral preoptic nucleus (VLPO), a brain region that promotes sleep, was examined. Compared to the control group, it was confirmed that ESK increased neural activity in VLPO GABAergic neurons that promote sleep, while SCH reversed neural activity. Therefore, it was confirmed that the *Girinchō* extract of the present invention promotes sleep by activating VLPO GABAergic neurons through A2A receptors.

[0096]

[0097] <2-4> Confirmation of A2A Receptor Binding Affinity of *Girinchō* Extract

[0098] To confirm the mechanism of the sleep-inducing effect of the *Girinchō* extract, its binding affinity with A2AR was examined. As a result, as shown in Figure 4, it was confirmed that the binding affinity of ESK to A2AR increased in a concentration-dependent manner at concentrations of 0.1, 0.3, and 0.9 mg / ml, with the binding affinities at each concentration being 33.6%, 64.7%, and 94.0%, respectively. Additionally, the IC50 value was 0.21 mg / ml, and the above results confirmed that A2AR is involved in the sleep-inducing mechanism of the *Girinchō* extract.

[0099]

[0100] <Example 3> Confirmation of sleep-inducing effect of compounds derived from *Girinchō* extract

[0101] <3-1> Identification of Compounds Derived from *Girinchō* Extract

[0102] UPLC-QTOF / MS analysis was performed to identify compounds within the *Girinchō* extract of the present invention and to select indicator components. Specifically, compounds were detected by UPLC-QTOF / MS analysis using *Girinchō* ethanol extract and *Girinchō* water extract as samples. Specifically, for the UPLC analysis, an ACQUITY C18 (1.7 μm, 2.1 mm × 100 mm) column was used in a Waters ACQUITY I-Class UPLC system (Waters Corp., Milford, MA, USA), and the column oven temperature was set to 40°C. The mobile phase solvents consisted of water (A) with 0.1% formic acid added and acetonitrile (B) with 0.1% formic acid added, and the mobile phase conditions were 0-2.5 min, B 2-15%; 2.5-4.5 min, B 15-18%; 4.5-7 min, B 18-20%; The analysis was conducted at 7–10 min, B 20–30%; 10–12 min, B 30–2%; and 12–15 min, B 2%. The column flow rate was 0.4 mL / min, and the UV wavelength was 280 nm. A sample injection volume of 2 μL was used. QTOF / MS analysis was performed using a Waters Xevo G3 QTOF / MS (Waters Corp.) system, utilizing electrospray ionization in ESI positive mode. The measurement parameters were set as follows: capillary voltage 3.0 kV; source temperature 120 ℃; cone voltage 40 V; cone gas flow 30 L / h; desolvation temperature 600 ℃; and desolvation gas flow 800 L / h. The measurement data were processed using UNIFI 3.8.0.23 (Waters Corp.).

[0103]

[0104] As a result, as shown in Fig. 5, it was confirmed that the extract of *Girinchō* of the present invention contains 10 types of compounds. In addition, it was confirmed that the peaks of the compounds contained in the ethanol extract and the hot water extract of *Girinchō* were different, and it was confirmed that the content of compounds derived from *Girinchō* was increased in the ethanol extract of *Girinchō* (Fig. 6).

[0105]

[0106] In addition, the UPLC retention time of compound 1 was 3.22 min, and it was confirmed to be a compound with a mass value of 459.09098[M+H]+ m / z as a result of QTOF / MS measurement (Fig. 7A).

[0107] The UPLC retention time of compound 2 was 3.34 min, and QTOF / MS measurement confirmed it to be a compound with a mass value of 633.11094[M+H]+ m / z (Fig. 7B).

[0108] The UPLC retention time of compound 3 was 3.99 min, and the QTOF / MS mass value was confirmed to be 199.05961[M+H]+ m / z. It was identified as ethyl gallate by structural analysis using NMR data (Fig. 7C).

[0109] The UPLC retention time of compound 4 was 4.19 min, and QTOF / MS measurement confirmed it to be a compound with a mass value of 639.15515[M+H]+ m / z (Fig. 8A).

[0110] The UPLC retention time of compound 5 was 5.51 min, and the QTOF / MS mass was confirmed to be 421.14557[M+Na]+ m / z. It was identified as Pulsatillanin A by structural analysis using NMR data (Fig. 8B).

[0111] The UPLC retention time of compound 6 was 5.43 min, and the QTOF / MS mass was confirmed to be 449.10542[M+H]+ m / z. It was identified as Quercitrin by structural analysis using NMR data (Fig. 8C).

[0112] The UPLC retention time of compound 7 was 6.36 min, and the QTOF / MS mass was confirmed to be 617.11461[M+H]+ m / z. It was identified as 2''-O-Galloylmyricitrin by structural analysis of NMR data (Fig. 9A).

[0113] The UPLC retention time of compound 8 was 6.48 min, and the QTOF / MS mass was confirmed to be 617.11461[M+H]+ m / z. It was identified as 3''-O-Galloylmyricitrin by structural analysis using NMR data (Fig. 9B).

[0114] The UPLC retention time of compound 9 was 8.37 min, and the QTOF / MS mass was confirmed to be 601.11668[M+H]+ m / z. It was identified as 2''-O-Galloylquercitrin by structural analysis using NMR data (Fig. 10A).

[0115] The UPLC retention time of compound 10 was 8.38 min, and the QTOF / MS mass was confirmed to be 601.11668[M+H]+ m / z. It was identified as 3''-O-Galloylquercitrin by structural analysis using NMR data (Fig. 10B).

[0116]

[0117] In addition, chromatography results confirmed the compound content of the ethanol extract and the hot water extract, and it was confirmed that the content of the compound with a mass value of 459.09 [M+H]+ (Compound 1) was significantly higher in the ethanol extract of *Girinchō*, and it was confirmed that the content of the compound was high in the ethanol extract of *Girinchō*, excluding the content of quercitrin (Fig. 11).

[0118]

[0119] <3-2> Confirmation of GABA Release Effect of Compounds Derived from *Girinchō* Extract

[0120] To confirm the sleep-inducing effect of the compounds in the *Girinchō* extract of the present invention, GABA-releasing ability was verified. Specifically, GABA-releasing ability was verified in the PC12 cell line, a mouse adrenal-derived cell line. Specifically, the pheochromocytoma PC12 cell line, derived from the adrenal medulla of mice, was obtained from ATCC (Manassas, VA, USA) and used. The cells were cultured in RPMI1640 medium (Gibco, MD, USA) supplemented with 10% horse serum (HS, Gibco, MD, USA), 5% fetal bovine serum (FBS, Gibco, MD, USA), and 1% penicillin / streptomycin (PS, Gibco, MD, USA) at 37°C under 5% CO2 conditions. Subsequently, to induce differentiation into neurons, PC12 cells were placed at a rate of 2 × 10⁶ per well. 5 Cells were inoculated into a 6-well plate at the specified concentration and cultured for 24 hours. Subsequently, RPMI1640 medium containing 50 ng / mL of nerve growth factor (NGF-7s; Sigma-Aldrich, St. Louis, MO, USA), 1% HS, 1% FBS, and 1% PS was added, and differentiation was carried out for 7 days. Afterward, the differentiated PC12 cells were treated with compounds derived from *Girinchō* and reacted for 24 hours. Subsequently, to quantify the GABA released by the cells, GABA release capacity was measured using a Rat GABA ELISA kit (Wuhan Fine Biotech Co., Ltd., Wuhan, China, Product No.: ER1707). After the end of culture, the cell culture supernatant was collected, centrifuged at 1,000 × g for 10 minutes to remove cell debris, and the supernatant was collected. The GABA concentration was then checked and quantified according to the manufacturer's protocol.

[0121]

[0122] As a result, as shown in Figure 12, it was confirmed that compounds 2 and 9 among the compounds derived from *Girinchō* had the best free energy and were useful components for improving sleep disorders.

[0123]

[0124] Accordingly, the present invention confirmed that the ethanol extract of *Scutellaria baicalensis* has an effect of improving sleep disorders by increasing sleep time and inducing sleep using A2A receptors. In addition, compounds within the ethanol extract of *Scutellaria baicalensis* were identified, and among the compounds derived from the ethanol extract of *Scutellaria baicalensis*, compounds with excellent GABA release ability for sleep induction were selected.

Claims

1. A pharmaceutical composition for the prevention or treatment of sleep disorders comprising *Girinchō* extract as an active ingredient.

2. In Paragraph 1, A composition wherein the above extract is extracted with a solvent selected from the group consisting of water, C1 to C4 lower alcohols, aqueous solutions of lower alcohols, hexane, acetone, ethyl acetate, and chloroform.

3. In Paragraph 1, The above-mentioned Girincho extract is a composition that induces sleep.

4. In Paragraph 3, A composition that induces the above sleep by reducing the sleep latency or increasing the total sleep time.

5. In Paragraph 4, A composition that induces the above sleep is A2A receptor-dependent.

6. In Paragraph 1, The above-mentioned Girincho extract comprises a compound selected from the group consisting of a compound with a mass value of 459.09098 [M+H]+, a compound with a mass value of 633.11094 [M+H]+, ethyl gallate, a compound with a mass value of 639.15515 [M+H]+, pulsatillanin A, quercitrin, 2"-O-galloylmyricitrin, 3"-O-galloylmyricitrin, 2"-O-galloylquercitrin, and 3"-O-galloylquercitrin.

7. In Paragraph 6, A composition in which the above compound has GABA-free ability.

8. In Paragraph 7, A composition in which the above-mentioned GABA-free ability induces sleep.

9. In Paragraph 1, A composition wherein the above sleep disorder is a disease selected from the group consisting of insomnia, sleep onset disorder, sleep maintenance disorder, early awakening disorder, deep sleep disorder, circadian rhythm sleep disorder, and sleep apnea.

10. A food composition for the prevention or improvement of sleep disorders containing *Girinchō* extract as an active ingredient.

11. A pharmaceutical composition for the prevention or treatment of sleep disorders comprising a compound derived from *Girinchō* as an active ingredient.

12. In Paragraph 11, A composition in which the above compound is a compound selected from the group consisting of a compound with a mass value of 459.09098[M+H]+, a compound with a mass value of 633.11094[M+H]+, ethyl gallate, a compound with a mass value of 639.15515[M+H]+, pulsatillanin A, quercitrin, 2"-O-galloylmyricitrin, 3"-O-galloylmyricitrin, 2"-O-galloylquercitrin, and 3"-O-galloylquercitrin.

13. In Paragraph 12, A composition in which the above compound has GABA-free ability.

14. A food composition for the prevention or improvement of sleep disorders comprising a compound derived from *Girinchō* as an active ingredient.